Protein phosphatase 2A activators reverse age-related behavioral changes by targeting neural cell senescence

Aging Cell. 2023 Mar;22(3):e13780. doi: 10.1111/acel.13780. Epub 2023 Jan 16.

Abstract

The contribution of cellular senescence to the behavioral changes observed in the elderly remains elusive. Here, we observed that aging is associated with a decline in protein phosphatase 2A (PP2A) activity in the brains of zebrafish and mice. Moreover, drugs activating PP2A reversed age-related behavioral changes. We developed a transgenic zebrafish model to decrease PP2A activity in the brain through knockout of the ppp2r2c gene encoding a regulatory subunit of PP2A. Mutant fish exhibited the behavioral phenotype observed in old animals and premature accumulation of neural cells positive for markers of cellular senescence, including senescence-associated β-galactosidase, elevated levels cdkn2a/b, cdkn1a, senescence-associated secretory phenotype gene expression, and an increased level of DNA damage signaling. The behavioral and cell senescence phenotypes were reversed in mutant fish through treatment with the senolytic ABT263 or diverse PP2A activators as well as through cdkn1a or tp53 gene ablation. Senomorphic function of PP2A activators was demonstrated in mouse primary neural cells with downregulated Ppp2r2c. We conclude that PP2A reduction leads to neural cell senescence thereby contributing to age-related behavioral changes and that PP2A activators have senotherapeutic properties against deleterious behavioral effects of brain aging.

Keywords: Age-related cognitive decline; DNA damage response neural senescence; PPP2R2C; protein phosphatase 2A; senolytics; senotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aniline Compounds / pharmacology
  • Animals
  • Animals, Genetically Modified
  • Behavior, Animal* / drug effects
  • Behavior, Animal* / physiology
  • Biomarkers / metabolism
  • Brain* / enzymology
  • Cellular Senescence* / drug effects
  • Cellular Senescence* / genetics
  • Cellular Senescence* / physiology
  • Cognitive Aging* / physiology
  • Cyclin-Dependent Kinase Inhibitor p15 / genetics
  • Cyclin-Dependent Kinase Inhibitor p15 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • DNA Damage
  • Gene Expression Regulation
  • Gene Knockout Techniques
  • Mice
  • Models, Animal
  • Mutation
  • Neurons* / drug effects
  • Neurons* / enzymology
  • Neurons* / physiology
  • Primary Cell Culture
  • Protein Phosphatase 2* / genetics
  • Protein Phosphatase 2* / metabolism
  • Senotherapeutics* / pharmacology
  • Sulfonamides / pharmacology
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • Zebrafish
  • beta-Galactosidase / genetics
  • beta-Galactosidase / metabolism

Substances

  • Aniline Compounds
  • beta-Galactosidase
  • Biomarkers
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16
  • navitoclax
  • Protein Phosphatase 2
  • Senotherapeutics
  • Sulfonamides
  • Tumor Suppressor Protein p53